Drug Profile
Research programme: specific androgen receptor modulator/lyase inhibitors - Eledon Pharmaceuticals
Alternative Names: SARM/LILatest Information Update: 07 Jan 2021
Price :
$50
*
At a glance
- Originator Tokai Pharmaceuticals
- Developer Eledon Pharmaceuticals
- Class
- Mechanism of Action Androgen receptor antagonists; Lyase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Prostate cancer
Most Recent Events
- 04 Jan 2021 Novus Therapeutics is now called Eledon Pharmaceuticals
- 04 Nov 2017 No recent reports of development identified for preclinical development in Prostate-cancer in USA
- 10 Nov 2014 Research programme: specific androgen receptor modulator/lyase inhibitors - Tokai is still in preclinical trials for Prostate cancer (castration-resistant ) in USA